Ipsen Limited is the UK subsidiary of Ipsen, a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000.
Ipsen Limited’s Endocrinology and Oncology Business Unit is responsible for a portfolio of products including Decapeptyl® (triptorelin), Increlex® (mecasermin), NutropinAq® (somatropin), Somatuline® (lanreotide) Autogel®, Somatuline® (lanreotide) LA, and Testim® 50mg Gel (testosterone).
The Neuromuscular Disorders Business Unit is responsible for Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex).
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!